William Blair analyst Brandon Vazquez has maintained their bullish stance on ZTS stock, giving a Buy rating on September 3.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Brandon Vazquez has given his Buy rating due to a combination of factors that highlight Zoetis’s potential for growth and innovation in the veterinary pharmaceutical market. A significant development is the positive opinion received for Portela, a long-acting monoclonal antibody for cats, from the European Medicines Agency’s Committee for Veterinary Medicinal Products. This advancement is expected to lead to a final approval and subsequent commercial launch in 2026, aligning with the company’s strategic timeline and reinforcing its pipeline execution capabilities.
Moreover, the anticipated approval of a long-acting monoclonal antibody for dogs by the end of 2025 is seen as a crucial growth driver. While the feline pain management market is relatively small, the canine segment is expected to have a more substantial impact on Zoetis’s stock performance. The introduction of these new products, along with the company’s strategic focus on clinical efficacy and safety, positions Zoetis to capitalize on expanding the pain management market. Despite the need for more detailed pricing and clinical data, the diversification of treatment options is viewed positively, supporting the Buy rating.
In another report released on September 3, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $173.00 price target.